Personalisation of antitumour drug therapy of disseminated gastric cancer within the framework of molecular classification
Authors: D.P. Guzhavin, G.G. Makiev, R.Sh. Abdulaeva, E.S. Obarevich, I.A. Vaniev, O.A. Kuznetsova, D.A. Gavrilova, A.A. Tryakin
DOI: https://www.doi.org/10.31917/2503281
The leading treatment for disseminated gastric cancer is chemotherapy, and survival rates for these patients are quite modest. The introduction of molecular classifications of malignancies improves the understanding of tumor biology and makes the study of personalized approaches to drug therapy more accessible. In this review article, the most accepted molecular classification of gastric cancer is examined, describing the molecular alterations characteristic of each of the subtypes. In addition, different therapeutic options depending on the alterations and subtypes, both already accepted and under development, are described. The delineation of molecular subtypes has not yet entered into routine practice, with the use of targeted drugs being limited to the identification of individual molecular genetic abnormalities. However, due to molecular classification, a large number of targeting drugs have been developed, which could be used in gastric cancer treatment in the future.